
Annual report 2024
added 12-13-2025
Midatech Pharma plc EBITDA 2011-2025 | MTP
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Midatech Pharma plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -7 M | -23 M | -11.3 M | -11.8 M | -13.3 M | -14.8 M | -12.2 M | -7.56 M | -4.25 M | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.25 M | -23 M | -11.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
234 M | $ 25.27 | -2.43 % | $ 1.22 B | ||
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-76.7 M | $ 4.75 | 1.61 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
-141 M | $ 3.26 | -3.12 % | $ 252 M | ||
|
AlloVir
ALVR
|
-200 M | - | 4.14 % | $ 49.1 M | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-130 M | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Kamada Ltd.
KMDA
|
-696 K | $ 7.03 | 0.14 % | $ 260 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 220.27 | 4.81 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-18.7 M | $ 0.91 | -5.01 % | $ 18.7 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 0.28 | -2.28 % | $ 609 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.3 | -3.51 % | $ 7.94 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | $ 89.78 | -0.57 % | $ 96.9 B | ||
|
Anika Therapeutics
ANIK
|
-81.2 M | $ 9.57 | 0.84 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
-396 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-89 M | - | -7.31 % | $ 87 M | ||
|
Benitec Biopharma
BNTC
|
-9.77 M | $ 12.05 | -7.06 % | $ 496 M | ||
|
Aytu BioScience
AYTU
|
-2.45 M | $ 2.34 | 2.59 % | $ 14.7 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
-12.5 M | - | -19.68 % | $ 18.4 M | ||
|
Arena Pharmaceuticals
ARNA
|
-620 M | - | -6.81 % | $ 3.04 B | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 1.29 | -3.01 % | $ 7.03 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Baudax Bio
BXRX
|
-56.6 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Catalyst Biosciences
CBIO
|
-66.2 M | $ 14.01 | -8.49 % | $ 922 M | ||
|
ChromaDex Corporation
CDXC
|
8.39 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
107 M | $ 566.18 | -2.56 % | $ 42.9 B | ||
|
Cerus Corporation
CERS
|
-12.4 M | $ 2.16 | 0.47 % | $ 399 M | ||
|
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-22.2 M | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
-217 M | - | -7.23 % | $ 13 M | ||
|
Biogen
BIIB
|
673 M | $ 174.42 | 1.11 % | $ 25.4 B | ||
|
BioVie
BIVI
|
-17.8 M | $ 1.42 | -5.96 % | $ 2.1 M | ||
|
Celldex Therapeutics
CLDX
|
-192 M | $ 27.36 | -2.09 % | $ 1.76 M | ||
|
Cortexyme
CRTX
|
-34.3 M | - | -1.05 % | $ 67.1 M | ||
|
Cellectar Biosciences
CLRB
|
-38.8 M | $ 3.63 | -3.97 % | $ 44.4 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-209 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-679 M | $ 11.54 | 0.87 % | $ 746 M |